FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.

Fujian Cosunter Pharmaceutical Co., Ltd.

300436

CNE100001YZ0

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 28/06/2024 am IST			5-day change	1st Jan Change
15.71 ^CNY	-1.19%		-2.12%	-38.70%

25/06	Fujian Cosunter Pharmaceutical Co., Ltd. Announces Directorate Appointments	CI
24/06	Fujian Cosunter Pharmaceutical Co., Ltd.(XSEC:300436) dropped from S&P Global BMI Index	CI

Fujian Cosunter Pharmaceutical Co., Ltd.(XSEC:300436) dropped from S&P Global BMI Index

June 24, 2024

Latest news about Fujian Cosunter Pharmaceutical Co., Ltd.

Fujian Cosunter Pharmaceutical Co., Ltd. Announces Directorate Appointments	26/06	CI
Fujian Cosunter Pharmaceutical Co., Ltd.(XSEC:300436) dropped from S&P Global BMI Index	24/06	CI
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	19/04	CI
Jiangsu Zhongxing Pharm Co., Ltd. cancelled the transaction announced on July 5, 2021	29/12	CI
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Fujian Cosunter Pharmaceutical Co., Ltd.(XSEC:300436) added to S&P Global BMI Index	18/23/18	CI
Fujian Cosunter Pharmaceutical Co., Ltd. agreed to acquire remaining 5.8333% stake in Jiangsu Zhongxing Pharm Co., Ltd. from Zhang Zhijun for CNY 10.6 million.	12/23/12	CI
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Cosunter Pharma Signs 14 Million Yuan Equipment Purchase Deal	27/23/27	MT
Fujian Cosunter Pharma's Unit Completes Clinical Trials on COVID-19 Drug	21/23/21	MT
Fujian Cosunter Pharma Gets Nod to Market Men's Drug	19/23/19	MT
Fujian Cosunter Pharma Completes Enrollment for COVID-19 Drug; Shares Drop 3%	05/23/05	MT
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	20/23/20	CI
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
Fujian Cosunter Pharma Unit Gets Drug Production License from Provincial Regulator	15/23/15	MT
Chinese Shares End Mixed; Cosunter Pharma Rallies 11% as COVID-19 Drug Seen More Effective Versus Pfizer's	10/23/10	MT
Fujian Cosunter Pharma Says COVID-19 Drug More Effective Than Pfizer’s Paxlovid; Shares Rally 14%	10/23/10	MT
Fujian Cosunter Pharma Selling 948 Million Yuan Shares to Fund New Drug Research Platform	09/23/09	MT
Fujian Cosunter Pharmaceutical Co., Ltd. announced that it expects to receive CNY 948 million in funding	05/23/05	CI
Fujian Cosunter Pharma Enrolls First Patient for Anti-COVID Drug Trial	22/22/22	MT
Fujian Cosunter’s Trial of Anti-COVID Tablets Shows Drug’s Safety; Shares Up 4%	12/22/12	MT
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	24/22/24	CI
Fujian Cosunter Subsidiary Gets Approval to Test Tablets for COVID-19 Patients	26/22/26	MT
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	27/22/27	CI
Fujian Cosunter Jintang Pharmaceutical Co., Ltd. announced that it expects to receive CNY 30 million in funding from Fujian Cosunter Pharmaceutical Co., Ltd.	27/22/27	CI

Chart Fujian Cosunter Pharmaceutical Co., Ltd.

Duration

Period

Chart Fujian Cosunter Pharmaceutical Co., Ltd.

More charts

Fujian Cosunter Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of nucleoside anti-HBV drugs. The Company's major products include Adefovir Dipivoxil Tablets, Lamivudine Tablets, Entecavir Capsules and other nucleoside anti-HBV drugs. The Company also produces over-the-counter (OTC) drugs, such as ferrous fumarate and ganoderma capsules.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.	-38.70%	348M
ELI LILLY AND COMPANY	+55.32%	819B
JOHNSON & JOHNSON	-6.75%	351B
MERCK & CO., INC.	+13.56%	329B
ABBVIE INC.	+10.68%	298B
ASTRAZENECA PLC	+16.57%	242B
ROCHE HOLDING AG	+2.04%	225B
NOVARTIS AG	+13.31%	217B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	158B

Other Pharmaceuticals